February 14, 2017 /
Click here to receive MS news via e-mail
Feb 9, 2017
Long-term
treatment with prolonged-release fampridine (Ampyra) offered persistent
clinical and subjective benefits in walking function in gait-impaired patients
with multiple sclerosis (MS), researchers reported.
treatment with prolonged-release fampridine (Ampyra) offered persistent
clinical and subjective benefits in walking function in gait-impaired patients
with multiple sclerosis (MS), researchers reported.
In an extension
study of the FAMPKIN trial, MS patients had an 11.5% improvement in walking
speed, a 10.7% improvement in endurance, and a 6.1-point improvement in
self-perceived ambulatory function over baseline during the first open-label
year of treatment, according to Linard Filli, PhD, of University Hospital
Zurich, and colleagues.
study of the FAMPKIN trial, MS patients had an 11.5% improvement in walking
speed, a 10.7% improvement in endurance, and a 6.1-point improvement in
self-perceived ambulatory function over baseline during the first open-label
year of treatment, according to Linard Filli, PhD, of University Hospital
Zurich, and colleagues.
Those effects
remained stable during a follow-up year of double-blind controlled treatment,
with improvements in those respective endpoints of 13.1%, 12%, and 7.4 points
compared with placebo, they reported online in Neurology.
remained stable during a follow-up year of double-blind controlled treatment,
with improvements in those respective endpoints of 13.1%, 12%, and 7.4 points
compared with placebo, they reported online in Neurology.
MS Views and News
Providing educational information, resources and services for those affected by MS, globally
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
